神经肌肉电刺激联合支链氨基酸预防活体肝移植术后肌少症的随机对照试验方案
本研究为开放标签随机平行组试验方案,计划纳入50例活体肝移植术后失代偿期肝硬化患者,随机接受神经肌肉电刺激(NMES)联合支链氨基酸(BCAA)或单纯NMES,干预3个月。主要终点为基线至3个月骨骼肌质量变化,次要终点包括基线至1个月骨骼肌质量及股四头肌力量变化,旨在评估联合治疗对术后肌少症的影响。
要点
- 活体肝移植术后患者易发生肌肉萎缩和肌少症,需物理治疗预防进展。
- NMES联合BCAA与单纯NMES的比较尚缺乏证据,本试验旨在填补空白。
- 主要终点为基线至3个月骨骼肌质量变化,采用InBody 770和超声评估。
核心结论
- 该试验方案旨在比较NMES联合BCAA与单纯NMES对活体肝移植术后失代偿期肝硬化患者骨骼肌的影响。
研究设计与样本
- 开放标签、随机、平行组试验,计划纳入50例活体肝移植术后失代偿期肝硬化患者。
- 患者随机分配至NMES联合BCAA组或单纯NMES组,干预持续3个月。
关键数值与推荐
- 主要终点为基线至3个月骨骼肌质量变化。
- 次要终点包括基线至1个月骨骼肌质量变化和基线至1个月股四头肌力量变化。
- 采用InBody 770体成分分析、体水分析和超声在肝移植前及术后4周、12周评估骨骼肌质量。
临床怎么用
- 若联合治疗有效,可为活体肝移植术后患者预防肌少症提供NMES联合BCAA的康复策略。
局限性
- 开放标签设计可能引入偏倚。
- 样本量50例较小,可能影响结果外推。
- 干预和随访仅3个月,长期效果未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Liver cirrhosis is the irreversible fibrosis of the liver and causes refractory ascites and hepatic encephalopathy, which might not respond to treatment. Living donor liver transplantation (LDLT) is an effective treatment for patients with cirrhosis. However, post-LDLT patients are prone to muscle atrophy and sarcopenia. Therefore, physiotherapy of post-LDLT patients is essential for preventing the progression of sarcopenia. Recently, rehabilitation using neuromuscular electrical stimulation (NMES) has been reported to be useful for preventing the progression of sarcopenia. Similarly, nutrition therapy is essential for post-LDLT patients because these patients frequently experience malnutrition. However, the effects of combined NMES and nutrition therapy on post-LDLT patients remain unknown. METHODS/DESIGN: This open-label, randomized, parallel-group study will compare the effects of combined therapy with NMES and branched-chain amino acids (BCAA) with those of NMES alone in patients with decompensated cirrhosis after LDLT. After LDLT, 50 patients with decompensated cirrhosis will be randomly assigned to receive NMES with BCAA or NMES without BCAA. The duration of the intervention will be 3 months. To analyze the change in skeletal muscle mass, InBody 770 body composition and body water analysis and ultrasonography will be performed before LDLT and 4 weeks and 12 weeks post-LDLT. The primary endpoint is changes in the skeletal muscle mass from baseline to 3 months. Important secondary endpoints are the changes in the skeletal muscle mass from baseline to 1 month and changes in the quadriceps strength from baseline to 1 month. DISCUSSION: The results of this study are expected to provide evidence regarding the effect of NMES combined with BCAA therapy on the skeletal muscle of post-LDLT patients. TRIAL REGISTRATION: Japan Registry of Clinical Research jRCTs071190051 . Registered on February 26, 2020.
引用
- Haraguchi M, Ichinose K, Miyaaki H, et al. Comparative study of the effect of neuromuscular electrical stimulation and oral administration of branched-chain amino acid on preventing sarcopenia in patients after living-donor liver transplantation: study protocol for an open-label randomized controlled trial. Trials. 2021. PMID: 33579345. doi:10.1186/s13063-021-05086-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。